EndoTODAY | EndoATLAS | ¿Ü·¡¼³¸íÀÚ·á

±â»ýÃæ | ½Äµµ | À§ | À§¾Ï | ESD | õ±â´©¼³

Home | Guide | ÁÖÀÎÀå | ±¸µ¶ | °Ë»ö | ¸µÅ©


[¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ¼ÒÈ­±âÇÐ ¿¬¼ö°­ÁÂ]

2015³â 10¿ù 11ÀÏ ÀÏ¿äÀÏ ¿¬¼¼´ë ¼ÒÈ­±â³»°ú¿¡¼­ ÁÖÃÖÇÑ ¼ÒÈ­±âÇÐ ¿¬¼ö°­Á¿¡ ȯÀÚ¾ÈÀü °­ÀÇÂ÷ ´Ù³à¿Ô½À´Ï´Ù (2015³â 10¿ù 11ÀÏ ¿¬¼¼´ëÇб³ ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ À¯ÀÏÇÑ È¦). ÀϺ» JDDW¿¡¼­ µ¹¾Æ¿Í ¹Ù·Î ¿¬¼¼´ë¿¡¼­ °­ÀǸ¦ ÇÏ·Á´Ï Á¶±Ý ¹÷Â÷±ä ÇßÁö¸¸... ÁغñµÈ ¹ßÇ¥µéÀÌ ¾ËÂ÷¼­ ÁÁÀº ½Ã°£À̾ú½À´Ï´Ù.


1. ºñ¸¸°ú ´ë»ç¼º ÁúȯÀÇ ³»½Ã°æ Ä¡·á - ¿¬¼¼´ëÇб³ ½Å¼º°ü

ºñ¸¸Àº º¸±â ½ÈÀº »óÅ°¡ ¾Æ´Ï¶ó Áúº´ÀÔ´Ï´Ù. ¼­¾çÀο¡ ºñÇÏ¿© µ¿¾çÀο¡¼­´Â µ¿ÀÏ BMI¿¡¼­ üÁö¹æ·üÀÌ ³ô°í ºñ¸¸°ü·Ã Áúȯµµ ¸¹±â ¶§¹®¿¡ ¼­¾çº¸´Ù ´Ù¼Ò tightÇÑ Áø´Ü±âÁØÀ» Àû¿ëÇØ¾ß ÇÕ´Ï´Ù.

ºñ¸¸ °ü·ÃÇÏ¿© À§¸¦ ¼ö¼úÇϸé üÁß°¨¼ÒÈ¿°ú¸¸ ÀÖÁö¸¸ ¼ÒÀåÀ» ¼ö¼úÇϸé üÁßÀÌ ºüÁú»Ó¸¸ ¾Æ´Ï¶ó ´ç´¢°ü·Ã ¿©·¯ ÁöÇ¥°¡ °³¼±µË´Ï´Ù. ¾ÆÁ÷±îÁö Àß ¾Ë·ÁÁöÁö ¾ÊÀº ±âÁØÀÌ ÀÖÀ» °ÍÀÔ´Ï´Ù. üÁß°¨¼Ò ½Ã¼ú ÈÄ ´ç´¢°¡ ÁÁ¾ÆÁö´Â ±âÀü Áß Çϳª·Î incretin À̶ó´Â È£¸£¸óÀÇ ¿ªÇÒÀÌ ÁÖ¸ñ¹Þ°í ÀÖ½À´Ï´Ù. ¿¹»óÄ¡ ¸øÇÑ ´Ù¸¥ ±âÀüµéµµ ¿¬±¸µÇ°í ÀÖ½À´Ï´Ù.

´ëÇÑÀÓ»ó¼ÒÈ­±â³»°ú 2015;2(3)

1) À§¿¡ ½Ã¼úÇÏ´Â ¹æ¹ý

(1) Apollo overstich¸¦ ÀÌ¿ëÇÑ sleeve gastrectomy

(2) Incisionless operating plateform

(3) Aspiration therapy: PEG¿Í ºñ½ÁÇÑ ¿ø¸®·Î À½½ÄÀ» ¸Ô°í PEG tube¸¦ ÅëÇØ À½½ÄÀ» »Ì¾Æ³»´Â ¹æ¹ý.

2) ¼ÒÀå¿¡ ½Ã¼úÇÏ´Â ¹æ¹ý

(1) Duodenal sleeve

(2) Duodenal mucosal resurfacing

* Âü°í: EndoTODAY ºñ¸¸


2. ´ëÀå¾Ï ¿¹¹æ°ú Á¶±â Áø´Ü - ¿¬¼¼´ëÇб³ ÀÌÇöÁ¤

¿ì¸®³ª¶ó¿¡¼­ ´ëÀå¾ÏÀº ³²ÀÚÀÇ °æ¿ì ¸Å³â 6.1%, ¿©ÀÚÀÇ °æ¿ì ¸Å³â 4.5% Áõ°¡ÇÏ°í ÀÖ½À´Ï´Ù.

Àüü ´ëÀå¾Ï ȯÀÚÀÇ ¾à 5-15%´Â À¯ÀüÀû ¿äÀο¡ ÀÇÇØ ¹ß»ýÇϸç, ºñ±³Àû Àß ¹àÇôÁø À¯Àü¼º ´ëÀå¾ÏÀº Àüü ´ëÀå¾ÏÀÇ ¾à 5%¸¦ Â÷ÁöÇÕ´Ï´Ù. ¿¹¸¦ µé¾î °¡Á·¼º¼±Á¾¼º¿ëÁ¾Áõ (FAP, 1%), À¯Àü¼º ºñ¿ëÁ¾Áõ ´ëÀå¾Ï (2-3 %), Æ÷ÀÌÃ÷-Á¦°Å½º ÁõÈıº, ¿¬¼Ò±â ¿ëÁ¾Áõ, MYH ¿ëÁ¾Áõ µîÀÌ ÀÖ½À´Ï´Ù.

MUTYH-associated polyposis (MAP)´Â Àͼ÷ÇÏÁö ¾ÊÀº ÁúȯÀÎÁö¶ó ¾Æ·¡¿¡ °£´ÜÈ÷ ¼Ò°³ÇÕ´Ï´Ù.

MUTYH-associated colorectal cancer and adenomatous polyposis (Surg Today 2014)

MUTYH-associated polyposis (MAP) was first described in 2002. MUTYH is a component of a base excision repair system that protects the genomic information from oxidative damage. When the MUTYH gene product is impaired by bi-allelic germline mutation, it leads to the mutation of cancer-related genes, such as the APC and/or the KRAS genes, via G to T transversion. MAP is a hereditary colorectal cancer syndrome inherited in an autosomal-recessive fashion. The clinical features of MAP include the presence of 10-100 adenomatous polyps in the colon, and early onset of colorectal cancer. Ethnic and geographical differences in the pattern of the MUTYH gene mutations have been suggested. In Caucasian patients, c.536A>G (Y179C) and c.1187G>A (G396D) mutations are frequently detected. In the Asian population, Y179C and G396D are uncommon, whereas other variants are suggested to be the major causes of MAP.

Information from cancer.net

ASCO recommends the following screening for people with MAP. It is important to discuss these options with your doctor, as each individual is different:
- Colonoscopy every one to two years, beginning at age 18 to 20.
- Yearly colonoscopy once a person develops polyps. Colectomy is the surgical removal of the entire colon. This may be considered if polyps cannot be managed with regular colonoscopies because there are too many.
- Upper endoscopy (EGD) at age 25 to 30 or once colorectal polyps are detected, whichever occurs first
- Yearly ultrasound of the thyroid may be considered starting at age 25 to 30
- Computed tomography (CT) scan or magnetic resonance imaging (MRI) if a person has a family history of desmoid tumors and a mutation on the APC gene that is linked with these tumors

2004³âºÎÅÍ 2008³â±îÁö ¿ì¸®³ª¶ó¿¡¼­ ½ÃÇàÇÑ ±¹°¡¾Ï°ËÁø ´ëº¯ÀáÇ÷°Ë»çÀÇ ¾ç¼º·üÀº 7.28%¿´½À´Ï´Ù. Àú´Â ÀÌ·± Áú¹®À» Çß½À´Ï´Ù.

¿ì¸®³ª¶ó¿¡¼­´Â ÀÌ»óÇÏ°Ôµµ ´ëÀå³»½Ã°æÀ» ¹ÞÀº »ç¶÷µµ °É·¯ÁöÁö ¾Ê°í ¸Å³â stool occult blood·Î °ÇÁøÀ» ¹ÞÀ¸¶ó´Â ÂÊÁö¸¦ ¹Þ°í ÀÖ½À´Ï´Ù. Á¤ºÎÀÇ ¹«Ã¥ÀÓÇÑ °ÇÁø Á¤Ã¥À¸·Î ÀÎÇÏ¿© À۳⿡ ´ëÀå³»½Ã°æÀ» ¹ÞÀº »ç¶÷ÀÌ ¿ÃÇØ¿¡µµ stool occult blood ¾ç¼ºÀ¸·Î ´ëÀå³»½Ã°æÀ» ¹ÞÀ¸¶ó´Â ±ÇÀ¯¸¦ ¹Þ°í ¿À½Ã´Â ºÐÀÌ Á¦¹ý ¸¹½À´Ï´Ù. ¾î¶»°Ô ÇϽôÂÁö¿ä?

Â÷Àç¸í ±³¼ö´Ô²²¼­ ÃÖ±Ù Am J Gastroenterol¿¡ ÀÌ¿¡ ´ëÇÑ ´äº¯ÀÌ ÀÖ¾ú´Ù°í comment ÇØ Áּ̽À´Ï´Ù (¾Æ·¡ ÃÊ·Ï ÂüÁ¶). ´ëÀå³»½Ã°æ ÈÄ stool occult blood °¡ ¾ç¼ºÀÌ¶óµµ interval cancer´Â °ÅÀÇ ¾ø´Ù°í ÇÕ´Ï´Ù. Á¦ °ÆÁ¤Àº ÀÏ´Ü ´ëº¯¿¡¼­ ÇÇ°¡ ³ª¿Ô´Ù°í ¿À½Å ºÐ¿¡°Ô 'À§ÇèÀÌ ³·À¸´Ï ±×³ç °¡¼¼¿ä'¶ó°í ¸»ÇÏ¸ç µÇµ¹·Áº¸³»±â´Â ¾î·Á¿ï °Í °°´Ù´Â °ÍÀÔ´Ï´Ù. ºÒÇÊ¿äÇÑ °Ë»ç´Â ¾ÈÇÏ´Â °ÍÀÌ »óÃ¥ÀÏ °Í °°½À´Ï´Ù.

Annual Fecal Occult Blood Testing can be Safely Suspended for up to 5 Years After a Negative Colonoscopy in Asymptomatic Average-Risk Patients (Liu. Am J Gastroenterol 2015)

Results: The mean age (68.9¡¾9.6 years), sex (95.2% male), and race (48.1% white, 32.1% black, 15.6% Hispanic, and 4.2% other) did not differ between the four groups. Overall, adenomas of any size were detected in 42.8% of patients, adenomas >= 10 mm in 14.7%, advanced neoplasms in 20.7%, and cancers in 7.3%. Advanced neoplasms were detected in 30.4% of patients who have never had a colonoscopy, 27% in those who have had one greater than 10 years prior, 10.0% in 5-10 years prior, and 1.1% in less than 5 years prior.

Conclusions: In asymptomatic average-risk patients with a negative colonoscopy within the last 5 years, the prevalence of adenomas is low, and no patient was diagnosed with cancer. These findings support the CDC recommendations to suspend annual FOBT for up to 5 years after a negative colonoscopy.

´ëÀå³»½Ã°æ ÈÄ ÃßÀû°Ë»ç¿¡ ´ëÇؼ­´Â ´ÙÀ½ link¸¦ Âü°íÇϱ⠹ٶø´Ï´Ù. colon_cancer_004.html


[2017-2-4. ÀÌÁØÇà Ãß°¡] ´ëÀå³»½Ã°æ °Ë»ç ÈÄ stool occult blood test´Â ÇÊ¿äÇÏÁö ¾Ê´Ù´Â °ÍÀÌ Áß·ÐÀÔ´Ï´Ù. ±×·¯³ª ¹Ìµð¾î¿¡¼­´Â '5.5.1 ¹ýÄ¢'ÀÌ ¼Ò°³µÇ°í ÀÖ½À´Ï´Ù. ¾ûÅ͸®µµ ÀÌ·± ¾ûÅ͸®°¡ ¾ø´Ù´Â »ý°¢ÀÔ´Ï´Ù.


3. °£¾Ï ¿¹¹æ ¹× Á¶±â °£¾Ï ¹ß°ß - ¿¬¼¼´ëÇб³ ±èµµ¿µ

¿ì¸®³ª¶ó´Â °£¿° °ü¸®¸¦ Àß ÇÏ°í ÀÖ´Â ³ª¶ó·Î ±¹Á¦ÀûÀ¸·Î âÂùÀ» ¹Þ°í ÀÖ´Ù´Â ¸»¾¸À» Çϼ̽À´Ï´Ù.

Antiviral therapy clearly reduces HCC incidence. Ç×¹ÙÀÌ·¯½º ÃÊÄ¡·á¿¡ ½ÇÆÐÇÏ¸é ¾àÀ» ¹Ù²ã¼­ Ä¡·á¸¦ Áö¼ÓÇØ¾ß ÇÑ´Ù°í ÇÕ´Ï´Ù.

°£¾Ï Á¶±âÁø´ÜÀ» À§ÇÏ¿© ultrasonography aloneÀº ºÎÁ·ÇÏ´Ù°í ÇÕ´Ï´Ù. Within MilanÀÌ 63%¶ó°í ÇÕ´Ï´Ù. Áï °£À̽ÄÀ» ½ÃµµÇÒ ¼ö ÀÖ´Â ´Ü°è¸¦ ³Ñ´Â »ç¶÷ÀÌ 1/3ÀÔ´Ï´Ù. AFP¸¦ ´õÇصµ ¹Î°¨µµ´Â 69% Á¤µµÀÔ´Ï´Ù.

Alpha FP (AFP) ÀÌ¿ÜÀÇ ÁÁÀº marker´Â ¾ÆÁ÷ ¾ø½À´Ï´Ù. DCP, AFP-L3 µîÀÌ ¾ð±ÞµÇ¾úÁö¸¸ ¼¼ºê¶õ½º º´¿ø ¿¬±¸¿¡¼­´Â negative data ¿´½À´Ï´Ù (Lim TS. Scand J Gastroenterol Epub).

Q and A¿¡¼­ ³ª¿Â ±èµµ¿µ ±³¼ö´Ô ´äº¯: CÇü °£¿°¿¡ ´ëÇÑ ÁÁÀº ¾àµéÀÌ ¸¹ÀÌ ³ª¿Ô½À´Ï´Ù. ºñ·Ï AST/ALT°¡ Á¤»óÀÌ´õ¶óµµ hepatitis C virus¸¦ °¡Áö°í ÀÖ´Â °ÍÀÌ È®ÀÎµÈ ¸ðµç »ç¶÷ÀÌ Ç×¹ÙÀÌ·¯½ºÁ¦ Ä¡·á ´ë»óÀ̶ó°í ÇÕ´Ï´Ù.


4. Á¤È®ÇÑ ÁøÁ¤Á¦ »ç¿ë°ú ¸ð´ÏÅ͸µ - ¿¬¼¼´ëÇб³ ¸¶Ãë°ú À¯¿µÃ¶

Malampati score°¡ 3 ȤÀº 4 ÀÎ °æ¿ì´Â ¸¶Ãë°ú Àǻ翡°Ô ÁøÁ¤À» ÀÇ·ÚÇ϶ó°í ±Ç°íµË´Ï´Ù. 3ÀΠȯÀÚ°¡ 10%, 4ÀΠȯÀÚ°¡ 1-2%ÀÔ´Ï´Ù.

À¯±³¼ö´ÔÀº ÁøÁ¤³»½Ã°æ¿¡¼­ routine ÇÏ°Ô »ê¼Ò¸¦ ÁÖ´Â °ÍÀÌ ÇÊ¿äÇÏ´Ù°í ÁÖÀåÇϼ̽À´Ï´Ù. ºñ¸¸, Æò¼Ò ÄÚ¸¦ °í´Â ȯÀÚ, airway°¡ ¾È ÁÁÀº ȯÀÚ¿¡¼­´Â ƯÈ÷ »ê¼Ò¸¦ ÁÖµµ·Ï ±ÇÇß½À´Ï´Ù. ÁøÁ¤ Àü¿¡ 5ºÐ Á¤µµ »ê¼Ò¸¦ Áְųª »ê¼Ò¸¦ ÀÌ¿ëÇÑ Å« È£ÈíÀ» ¸î¹ø ÇÏ´Â °Íµµ ÁÁ´Ù°í Á¦¾ÈÇÏ¿´½À´Ï´Ù. °í¹ÎÀÔ´Ï´Ù. Çö½ÇÀûÀÎ ¾î·Á¿òÀÌ ÀûÁö ¾Ê±â ¶§¹®ÀÔ´Ï´Ù. ¹ø°Å·Ó±âµµ ÇÏ°í, ¸Å¹ø nasal prongÀ» ¹Ù²Ù´Â °Íµµ ºÒÆíÇÏ°í, °Ë»ç ÁøÇà ¼Óµµµµ ´Ê¾îÁú °Í °°°í, ÀÇ·áÁøÀÌ ¹æ½ÉÇÒ±î °ÆÁ¤µÇ±âµµ ÇÏ°í...


5. ´ëÀå³»½Ã°æ Áú°ü¸® - °æÈñ´ëÇб³ Â÷Àç¸í

Â÷Àç¸í ±³¼ö´ÔÀº ¾¾¾ÖƲÀÇ Virginia Mason Medical Center°¡ ÀûÀÚ¸¦ Ÿ°³Çϱâ À§ÇÏ¿© ºñ¿ëÀý°¨¿¡ ¸ôµÎÇÏÁö ¾Ê°í ÁúÇà»ó ³ë·ÂÀ» Çؼ­ ÈæÀÚÀüȯµÈ »ç·Ê¸¦ ¼Ò°³Çß½À´Ï´Ù.

CecumÀ» ¸Ö¸®¼­ Àá±ñ º¸¾Ò´Ù°í cecal intubationÀÌ µÈ °ÍÀ¸·Î °£ÁÖÇÏ¸é ¾ÈµË´Ï´Ù. ±âÁØÀÌ »ó´çÈ÷ ¾ö°ÝÇß½À´Ï´Ù (¾Æ·¡ »çÁø ÂüÁ¶).

´ëÀå Á¤°áÀº ³²¾ÆÀÖ´Â ¹°À» ¸ðµÎ Á¦°ÅÇÑ ÈÄ Æò°¡ÇÏ´Â Boston scaleÀ» ±ÇÇÕ´Ï´Ù.


6. ³»½Ã°æ½ÇÀÇ È¯ÀÚ¾ÈÀü°ú ÀÇ·áÁø ¾ÈÀü - ¼º±Õ°ü´ëÇб³ ÀÌÁØÇà (ÁÂÀåÀº ¿¬¼¼´ëÇб³ ¹ÚÈ¿Áø ±³¼ö´Ô²²¼­ ¼ö°íÇØ Áּ̽À´Ï´Ù)

Àú´Â "¸Þ¸£½º ¶§ ´À³¢¼Ì°ÚÁö¸¸ ¾ÈÀüÀº °³°³ÀÎÀÇ ³ë·Â¸¸À¸·Î ÀÌ·ê ¼ö ÀÖ´Â ±×·± ÀÏÀÌ ¾Æ´Õ´Ï´Ù. Å« ÅõÀÚ¿Í ½Ã½ºÅÛ °³¹ß ¹× Áö¼ÓÀûÀÎ ¹Ýº¹ ÈÆ·ÃÀÌ ÀüÁ¦µÇ¾î¾ß ÇÕ´Ï´Ù. ¿À´ÃÀº ¼ÒÈ­±â³»°ú Çà»ç¶ó´Â Á¡À» °í·ÁÇÏ¿© Áö±ÝºÎÅÍ ³ªºÎÅÍ ÇÒ ¼ö ÀÖ´Â ÀÏ µÎ °¡Áö¸¦ Áß½ÉÀ¸·Î ¸»¾¸µå¸®°Ú½À´Ï´Ù."·Î ½ÃÀÛÇÏ¿© critical value report (CVR)°ú ergonomics¿¡ ´ëÇÏ¿© °­ÀÇÇÏ¿´½À´Ï´Ù.


[References]

1) 2015³â ¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ¼ÒÈ­±âÇÐ ¿¬¼ö°­Á - ºñ¸¸, ´ëÀå¾Ï ¿¹¹æ°ú Á¶±â Áø´Ü, °£¾Ï ¿¹¹æ, ´ëÀå³»½Ã°æ Áú°ü¸®

2) 2016³â ¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ¼ÒÈ­±âÇÐ ¿¬¼ö°­Á - belching/bloating, hepatitis C

© EndoTODAY Endoscopy Learning Center. Jun Haeng Lee. ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò ÀÌÁØÇà